NCT02720367View on ClinicalTrials.gov

Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

January 31, 2018

Study Completion Date

March 31, 2020

Conditions
Urinary Bladder Cancer
Interventions
DRUG

Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200

TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical system whose primary mode of action is the controlled release of gemcitabine into the bladder over an indwelling period.

Trial Locations (2)

Unknown

Canisius Wilhelmina Ziekenhuis, Nijmegen

Radboudumc, Nijmegen

All Listed Sponsors
lead

Taris Biomedical LLC

INDUSTRY

NCT02720367 - Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer | Biotech Hunter | Biotech Hunter